PharmaShots Weekly Snapshot (July 08 – 12, 2019)

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine


1.Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

Published: Jul 12, 2019 | Tags: Eli Lilly, Reports, Results, Emgality, galcanezumab-gnlm, Three, P-III, Studies, Chronic, Episodic Migraine

Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s Disease in Canada

2. Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s Disease in Canada

Published: Jul 10, 2019 | Tags: Valeo, Launches, Onstryv, safinamide tablet, Treatment, Parkinson, Disease, Canada

Ono Pharmaceutical Signs an Exclusive License Agreement with Forty Seven to Develop and Commercialize 5F9 in Selected Asian Countries

3. Ono Pharmaceutical Signs an Exclusive License Agreement with FortySeven to Develop and Commercialize 5F9 in Selected Asian Countries

Published: Jul 11, 2019 | Tags: Ono Pharmaceutical, Signs, Exclusive, License Agreement, Forty Seven, Develop, Commercialize, 5F9, Selected, Asian Countries, Japan, South Korea, Taiwan

Abbott’s Alinity S System Receives FDA’s Approval for Blood and Plasma Screening in the US

4. Abbott’s Alinity S System Receives FDA’s Approval for Blood and Plasma Screening in the US

Published: Jul 11, 2019 | Tags: Abbott, Alinity S System, Receives, FDA, Approval, Blood, Plasma, Screening, US

Novartis, Amgen and Banner Alzheimer's Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer's Disease

5. Novartis, Amgen and Banner Alzheimer’s Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer’s Disease

Published: Jul 11, 2019 | Tags: Novartis, Amgen, Banner Alzheimer’s Institute, Terminate, Two, P-II/III, Studies, CNP520, umibecestat, Prevention, Alzheimer’s Disease

I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

6. I-Mab Signs an Exclusive License Agreement with MacroGenics to Develop and Commercialize Enoblituzumab in Greater China

Published: Jul 10, 2019 | Tags: I-Mab, Signs, Exclusive, License, Agreement, MacroGenics, Develop, Commercialize, Enoblituzumab, Greater China

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III Study for Episodic Cluster Headache

7. Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III Study for Episodic Cluster Headache Published: Jul 11, 2019 | Tags:Eli Lilly, Reports, Results, Emgality, galcanezumab-gnlm, P-III, Study, Episodic Cluster Headache

Amazon’s AI-Powered Alexa to Deliver NHS Health Advice in the UK

8. Amazon’s AI-Powered Alexa to Deliver NHS Health Advice in the UK

Published: Jul 10, 2019 | Tags: NHS, Collaborates, Amazon, Alexa, Deliver, NHS, Health Advice, UK

Takeda’s Vyvanse (lisexamfetamine dimesylate) Chewable Tablet Receives Health Canada’s Approval for the Treatment of Patients with Attention Deficit/Hyperactivity Disorder Aged≥ 6yrs.

9. Takeda’s Vyvanse (lisexamfetamine dimesylate) Chewable Tablet Receives Health Canada’s Approval for the Treatment of Patients with Attention-Deficit/Hyperactivity Disorder Aged≥ 6yrs.

Published: Jul 10, 2019 | Tags: Takeda, Vyvanse, lisexamfetamine dimesylate, Chewable Tablet, Receives, Health Canada, Approval, Treatment, Patients, Attention Deficit/Hyperactivity Disorder, Aged≥ 6yrs.

Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

10. Torrent Signs a Non-Exclusive License Agreement with Glenmark to Co-Commercialize Remogliflozin Etabonate for Type 2 Diabetes in India

Published: Jul 11, 2019 | Tags: Torrent, Signs, Non-Exclusive, License Agreement, Glenmark, Co-Commercialize, Remogliflozin Etabonate, India

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

11. Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for Multiple Myeloma

Published: Jul 10, 2019 | Tags: Celgene, Pomalyst, pomalidomide, Triple Regimen, Receive, Health Canada, Approval, Multiple Myeloma

Sandoz Launches Pre-Filled Epinephrine Injection for Type 1 Allergic Reactions in the US

12. Sandoz Launches Pre-Filled Epinephrine Injection for Type 1 Allergic Reactions in the US

Published: Jul 10, 2019 | Tags: Sandoz, Launches, Pre-Filled, Epinephrine, Injection, Type 1, Allergic Reactions, US

Jazz Pharmaceuticals Acquires Redx Pharma’s Pre-clinical Pan-RAF Inhibitor Program for RAF and RAS Mutant Tumors

13. Jazz Pharmaceuticals Acquires Redx Pharma’s Pre-clinical Pan-RAF Inhibitor Program for RAF and RAS Mutant Tumors

Published: Jul 10, 2019 | Tags:  Jazz Pharmaceuticals, Acquires, Redx Pharma, Pre-clinical, Pan-RAF Inhibitor Program, RAF, RAS, Mutant Tumors

Janssen Signs an Agreement with Celsius Therapeutics to Identify Response Biomarkers for Ulcerative Colitis

14.Janssen Signs an Agreement with Celsius Therapeutics to Identify Response Biomarkers for Ulcerative Colitis

Published: Jul 09, 2019 | Tags: Janssen, Signs, Agreement, Celsius Therapeutics, Identify, Response Biomarkers, Ulcerative Colitis

Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumors

15. Mirati Signs a Non-Exclusive Clinical Collaboration with Novartis to Evaluate the Combination of MRTX849 and TNO155 for Solid Tumors

Published: Jul 09, 2019 | Tags: Mirati, Signs, Non-Exclusive, Agreement, Novartis, Evaluate, Combination, MRTX849, TNO155, Solid Tumors

ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

16. ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

Published: Jul 10, 2019 | Tags: ViiV Healthcare, Reports, Results, Dual-Drug Regimen, P-III, TANGO, Study, HIV-1 Infection

Sanofi Reports FDA’s Acceptance of BLA to Review Isatuximab for Relapsed/Refractory Multiple Myeloma Sanofi Reports FDA’s Acceptance of BLA to Review Isatuximab for Relapsed/Refractory Multiple Myeloma

17. Sanofi Reports FDA’s Acceptance of BLA to Review Isatuximab for Relapsed/Refractory Multiple Myeloma

Published: Jul 10, 2019 | Tags: Sanofi, Reports, FDA, Acceptance, BLA, Review, Isatuximab, Relapsed/Refractory, Multiple Myeloma

Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

18. Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

Published: Jul 08, 2019 | Tags: Boehringer Ingelheim, Reports, Results, Pradaxa, dabigatran etexilate mesylate, Management, Venous Thromboembolism, Children

Merck Reports FDA’s Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications

19.Merck Reports FDA’s Acceptance of sBLA of Keytruda (pembrolizumab) with Six-Week Dosing Schedule for Multiple Indications

Published: Jul 09, 2019 | Tags: Merck, Reports, FDA, Acceptance, sBLA, Keytruda, pembrolizumab, Six-Week, Dosing Schedule, Multiple Indications

The US Department of Defense Awarded Contract to SIGA for Expanded Indication of TPOXX (tecovirimat) for $19.5M

20. The US Department of Defense Awarded Contract to SIGA for Expanded Indication of TPOXX (tecovirimat) for $19.5M

Published: Jul 08, 2019 | Tags: The US Department of Defense, Awarded, Contract, SIGA, Expanded Indication, TPOXX, tecovirimat, $19.5M

Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A

21. Roche Reports Updated Results of Hemlibra (emicizumab) in P-III HAVEN and P-IIIb STASEY Studies for Hemophilia A

Published: Jul 09, 2019 | Tags: Roche, Reports, Updated, Results, Hemlibra, emicizumab, P-III, HAVEN, P-IIIb, STASEY, Studies, Hemophilia A

Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

22. Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

Published: June 08, 2019 | Tags: Bayer, Reports, Results, Xarelto, rivaroxaban, P-III, EINSTEIN-Jr., Study, Venous Thromboembolism

ViiV Healthcare Initiates CUSTOMIZE Study of Dual- Drug Injectable Regimen for the Treatment of HIV

23.ViiV Healthcare Initiates CUSTOMIZE Study of Dual-Drug Injectable Regimen for the Treatment of HIV

Published: Jul 08, 2019 | Tags: ViiV Healthcare, Initiates, CUSTOMIZE, Study, Dual-Drug, Injectable Regimen, Treatment, HIV

Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study for Personalized Prophylaxis in Patients with Severe Hemophilia A

24. Takeda Reports Updated Results of Adynovate in P-IIIb/IV PROPEL Study for Personalized Prophylaxis in Patients with Severe Hemophilia A

Published: Jul 08, 2019 | Tags: Takeda, Reports, Updated, Results, Adynovate, P-IIIb/IV, PROPEL, Study, Personalized Patients, Severe, Hemophilia A

Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

25. Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

Published: Jul 08, 2019 | Tags: Novo Nordisk, Reports, Results, Refixia, nonacog beta pegol, Two, P-III, Studies, Hemophilia B, Children

Isansys Lifecare Develops Patient Status Engine Wearable Body Patch for the Detection of Sepsis

26. Isansys Lifecare Develops Patient Status Engine Wearable Body Patch for the Detection of Sepsis

Published: Jul 05, 2019 | Tags: Isansys Lifecare, Develops, Patient Status Engine, Wearable, Body Patch, Detection, Sepsis

BeiGene’s Tislelizumab Receives NMPA’s Priority Review to sNDA for Urothelial Carcinoma in China

27. BeiGene’s Tislelizumab Receives NMPA’s Priority Review to sNDA for Urothelial Carcinoma in China

Published: Jul 07, 2019 | Tags: BeiGene, Tislelizumab, Receives, NMPA, Priority Review, sNDA, Urothelial Carcinoma, China

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post